High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study
Richard A. Nash(Colorado Blood Cancer Institute), Daniel E. Furst(University of California, Los Angeles), Keith M. Sullivan(Duke Medical Center), Chien-Shing Chen(Loma Linda University), Gretchen Henstorf(Fred Hutch Cancer Center), Muneer H. Abidi(Spectrum Health), Mark H. Wener(University of Washington), James R. Seibold(University of Michigan), Leslie J. Crofford(Vanderbilt University Medical Center), Federico Viganego(Fred Hutch Cancer Center), Rainer Storb(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Charles F. LeMaistre(CHRISTUS Transplant Institute), J. David Godwin(University of Washington), B McLaughlin(Fred Hutch Cancer Center), Peter A. McSweeney(Mesoblast (United States)), Howard M. Shulman(Fred Hutch Cancer Center), Jerry A. Molitor(Virginia Mason Medical Center), J. Lee Nelson(University of Washington), Kevin T. McDonagh(University of Michigan), Leona Holmberg, Theodore A. Gooley(Leipzig University), Maureen D. Mayes(The University of Texas Health Science Center)
Cited by 264
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis & Rheumatology|2015|2.8k
Chronic graft-versus-host syndrome in man
|The American Journal of Medicine|1980|2.4k